Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast Cancer
George Sledge, Jr., MD, discusses the overall survival data of the phase III MONARCH-2 trial in advanced hormone receptor-positive, HER2-negative breast cancer.
George Sledge, Jr., MD, professor of medicine (oncology) at Stanford University Medical Center, discusses the overall survival (OS) data of the phase III MONARCH-2 trial in advanced hormone receptor (HR)positive, HER2-negative breast cancer.
Data presented at the 2019 ESMO Congress demonstrated that the combination of abemaciclib (Verzenio) and fulvestrant (Faslodex) demonstrated a median 9.4-month OS benefit versus fulvestrant and placebo in patients with advanced HRpositive, HER2-negative breast cancer who progressed on prior endocrine therapy. These data are both statistically significant and clinically important, says Sledge.
At a median follow-up of 47.7 months, the median OS with the combination of abemaciclib and fulvestrant was 46.7 months versus 37.3 months with placebo/fulvestrant (HR, 0.757; 95% CI, 0.606-0.945;P
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
